US 11,952,349 B2Granted

Anti-cancer nuclear hormone receptor-targeting compounds

AssigneeNuvation Bio Inc.

InventorsSon Minh Pham, Jayakanth Kankanala, Jeremy Pettigrew, Christopher Paul Miller

Life of this patent

Estimating the term…

Abstract

The disclosure relates to anti-cancer compounds derived from a payload which binds to poly(ADP-ribose) polymerase (PARP) and a nuclear steroid-targeting epitope (B of Formula I), which components are covalently linked via a linker, to products containing the same, as well as to methods of their use and preparation.

Claims10

Dependent claims

A compound of Formula A-L-B, wherein:

A is A1 or A4, wherein:
L is L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11, L12, L13, L14, L15, L16, L17, L18, L19, L20, L21, L22, L23, L24, L25, L26, L27, L28, L29, L30, L31, L32, L33, L34, L35, L36, L37, L38, L39, L40, L41, L42, L43, L44, L45, or L46, wherein:
and;
B is B1, B2, B3, B4, B5, B6, B7, B8, B9, B10, B11, B12, B13, B14, B4-5-B16, B17, B18, or B19, wherein:
and further wherein the “*” in A1 and A4 and each L moiety denotes a covalent bond therebetween, and the wavy line in each L and B denotes a covalent bond therebetween;
wherein the compound of Formula A-L-B is selected from:
A1-L1-B1
A1-L1-B2
A1-L1-B3
A1-L1-B4
A1-L1-B5
A1-L1-B6
A1-L1-B7
A1-L1-B8
A1-L1-B9
A1-L1-B10
A1-L1-B11
A1-L1-B12
A1-L1-B13
A1-L2-B1
A1-L2-B2
A1-L2-B3
A1-L2-B4
A1-L2-B5
A1-L2-B6
A1-L2-B7
A1-L2-B8
A1-L2-B9
A1-L2-B10
A1-L2-B11
A1-L2-B12
A1-L2-B13
A1-L3-B1
A1-L3-B2
A1-L3-B3
A1-L3-B4
A1-L3-B5
A1-L3-B6
A1-L3-B7
A1-L3-B8
A1-L3-B9
A1-L3-B10
A1-L3-B11
A1-L3-B12
A1-L3-B13
A1-L4-B1
A1-L4-B2
A1-L4-B3
A1-L4-B4
A1-L4-B5
A1-L4-B6
A1-L4-B7
A1-L4-B8
A1-L4-B9
A1-L4-B10
A1-L4-B11
A1-L4-B12
A1-L4-B13
A1-L5-B1
A1-L5-B2
A1-L5-B3
A1-L5-B4
A1-L5-B5
A1-L5-B6
A1-L5-B7
A1-L5-B8
A1-L5-B9
A1-L5-B10
A1-L5-B11
A1-L5-B12
A1-L5-B13
A1-L6-B1
A1-L6-B2
A1-L6-B3
A1-L6-B4
A1-L6-B5
A1-L6-B6
A1-L6-B7
A1-L6-B8
A1-L6-B9
A1-L6-B10
A1-L6-B11
A1-L6-B12
A1-L6-B13
A1-L7-B1
A1-L7-B2
A1-L7-B3
A1-L7-B4
A1-L7-B5
A1-L7-B6
A1-L7-B7
A1-L7-B8
A1-L7-B9
A1-L7-B10
A1-L7-B11
A1-L7-B12
A1-L7-B13
A1-L8-B1
A1-L8-B2
A1-L8-B3
A1-L8-B4
A1-L8-B5
A1-L8-B6
A1-L8-B7
A1-L8-B8
A1-L8-B9
A1-L8-B10
A1-L8-B11
A1-L8-B12
A1-L8-B13
A1-L9-B1
A1-L9-B2
A1-L9-B3
A1-L9-B7
A1-L9-B8
A1-L9-B9
A1-L9-B11
A1-L9-B13
A1-L20-B1
A1-L20-B2
A1-L20-B3
A1-L20-B4
A1-L20-B5
A1-L20-B6
A1-L20-B7
A1-L20-B8
A1-L20-B9
A1-L20-B10
A1-L20-B11
A1-L20-B12
A1-L20-B13
A1-L21-B1
A1-L21-B2
A1-L21-B3
A1-L21-B4
A1-L21-B5
A1-L21-B6
A1-L21-B7
A1-L21-B8
A1-L21-B9
A1-L21-B10
A1-L21-B11
A1-L21-B12
A1-L21-B13
A1-L22-B1
A1-L22-B2
A1-L22-B3
A1-L22-B4
A1-L22-B5
A1-L22-B6
A1-L22-B7
A1-L22-B8
A1-L22-B9
A1-L22-B10
A1-L22-B11
A1-L22-B12
A1-L22-B13
A1-L23-B1
A1-L23-B2
A1-L23-B3
A1-L23-B4
A1-L23-B5
A1-L23-B6
A1-L23-B7
A1-L23-B8
A1-L23-B9
A1-L23-B10
A1-L23-B11
A1-L23-B12
A1-L23-B13
A1-L24-B1
A1-L24-B2
A1-L24-B3
A1-L24-B4
A1-L24-B5
A1-L24-B6
A1-L24-B7
A1-L24-B8
A1-L24-B9
A1-L24-B10
A1-L24-B11
A1-L24-B12
A1-L24-B13
A1-L30-B1
A1-L30-B2
A1-L30-B3
A1-L30-B4
A1-L30-B5
A1-L30-B6
A1-L30-B7
A1-L30-B8
A1-L30-B9
A1-L30-B10
A1-L30-B11
A1-L30-B12
A1-L30-B13
A1-L31-B1
A1-L31-B2
A1-L31-B3
A1-L31-B4
A1-L31-B5
A1-L31-B6
A1-L31-B7
A1-L31-B8
A1-L31-B9
A1-L31-B10
A1-L31-B11
A1-L31-B12
A1-L31-B13
A1-L32-B1
A1-L32-B2
A1-L32-B3
A1-L32-B7
A1-L32-B8
A1-L32-B9
A1-L32-B11
A1-L32-B13
A1-L39-B1
A1-L39-B2
A1-L39-B3
A1-L39-B4
A1-L39-B5
A1-L39-B6
A1-L39-B7
A1-L39-B8
A1-L39-B9
A1-L39-B10
A1-L39-B11
A1-L39-B12
A1-L39-B13
A1-L40-B1
A1-L40-B2
A1-L40-B3
A1-L40-B4
A1-L40-B5
A1-L40-B6
A1-L40-B7
A1-L40-B8
A1-L40-B9
A1-L40-B10
A1-L40-B11
A1-L40-B12
A1-L40-B13
A1-L41-B1
A1-L41-B2
A1-L41-B3
A1-L41-B4
A1-L41-B5
A1-L41-B6
A1-L41-B7
A1-L41-B8
A1-L41-B9
A1-L41-B10
A1-L41-B11
A1-L41-B12
A1-L41-B13
A1-L42-B1
A1-L42-B2
A1-L42-B3
A1-L42-B4
A1-L42-B5
A1-L42-B6
A1-L42-B7
A1-L42-B8
A1-L42-B9
A1-L42-B10
A1-L42-B11
A1-L42-B12
A1-L42-B13
A1-L43-B1
A1-L43-B2
A1-L43-B3
A1-L43-B4
A1-L43-B5
A1-L43-B6
A1-L43-B7
A1-L43-B8
A1-L43-B9
A1-L43-B10
A1-L43-B11
A1-L43-B12
A1-L43-B13
A1-L44-B1
A1-L44-B2
A1-L44-B3
A1-L44-B7
A1-L44-B8
A1-L44-B9
A1-L44-B11
A1-L44-B13
A1-L20-B14
A1-L21-B14
A1-L22-B14
A1-L23-B14
A1-L24-B14
A1-L2-B14
A1-L3-B14
A1-L45-B14
A1-L20-B16
A1-L21-B16
A1-L22-B16
A1-L23-B16
A1-L24-B16
A1-L2-B16
A1-L3-B16
A1-L45-B16
A1-L20-B17
A1-L21-B17
A1-L22-B17
A1-L23-B17
A1-L24-B17
A1-L2-B17
A1-L3-B17
A1-L45-B17
A1-L20-B18
A1-L21-B18
A1-L22-B18
A1-L23-B18
A1-L24-B18
A1-L2-B18
A1-L3-B18
A1-L45-B18
A1-L20-B19
A1-L21-B19
A1-L22-B19
A1-L23-B19
A1-L24-B19
A1-L2-B19
A1-L3-B19
A1-L45-B19
A4-L46-B10
A4-L18-B10
A4-L19-B10
A4-L46-B16
A4-L18-B16
A4-L19-B16
A4-L46-B6
A4-L18-B6
A4-L19-B6 and
A1-L45-B10
or a stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog or pharmaceutically acceptable salt thereof.

338 more elements

Dependencies are inferred from the claim text.

Facts

Application: 17/096,743Filed 12 Nov 2020 · us provisional application
Priority: 13 Nov 2019
Published: US 2021/0214316 A115 Jul 2021
Granted: 9 Apr 2024
Term ends: Not estimatedThe source records don’t support an estimate.

Classification5 codes

C07D 237/32
Phthalazines: with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
C07J 43/003
Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopentahydrophenanthrene skeleton: not condensed
C07J 71/0047
Nitrogen only: at position 2
C07D
Heterocyclic compounds

Family

Application62/935,065Us provisional application · filed 13 Nov 2019
US 2021/0214316 A1Pre-grant publication · published 15 Jul 2021
US 11,952,349 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

A compound of Formula A-L-B, wherein:

A is A1 or A4, wherein:
L is L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11, L12, L13, L14, L15, L16, L17, L18, L19, L20, L21, L22, L23, L24, L25, L26, L27, L28, L29, L30, L31, L32, L33, L34, L35, L36, L37, L38, L39, L40, L41, L42, L43, L44, L45, or L46, wherein:
and;
B is B1, B2, B3, B4, B5, B6, B7, B8, B9, B10, B11, B12, B13, B14, B4-5-B16, B17, B18, or B19, wherein:
and further wherein the “*” in A1 and A4 and each L moiety denotes a covalent bond therebetween, and the wavy line in each L and B denotes a covalent bond therebetween;
wherein the compound of Formula A-L-B is selected from:
A1-L1-B1
A1-L1-B2
A1-L1-B3
A1-L1-B4
A1-L1-B5
A1-L1-B6
A1-L1-B7
A1-L1-B8
A1-L1-B9
A1-L1-B10
A1-L1-B11
A1-L1-B12
A1-L1-B13
A1-L2-B1
A1-L2-B2
A1-L2-B3
A1-L2-B4
A1-L2-B5
A1-L2-B6
A1-L2-B7
A1-L2-B8
A1-L2-B9
A1-L2-B10
A1-L2-B11
A1-L2-B12
A1-L2-B13
A1-L3-B1
A1-L3-B2
A1-L3-B3
A1-L3-B4
A1-L3-B5
A1-L3-B6
A1-L3-B7
A1-L3-B8
A1-L3-B9
A1-L3-B10
A1-L3-B11
A1-L3-B12
A1-L3-B13
A1-L4-B1
A1-L4-B2
A1-L4-B3
A1-L4-B4
A1-L4-B5
A1-L4-B6
A1-L4-B7
A1-L4-B8
A1-L4-B9
A1-L4-B10
A1-L4-B11
A1-L4-B12
A1-L4-B13
A1-L5-B1
A1-L5-B2
A1-L5-B3
A1-L5-B4
A1-L5-B5
A1-L5-B6
A1-L5-B7
A1-L5-B8
A1-L5-B9
A1-L5-B10
A1-L5-B11
A1-L5-B12
A1-L5-B13
A1-L6-B1
A1-L6-B2
A1-L6-B3
A1-L6-B4
A1-L6-B5
A1-L6-B6
A1-L6-B7
A1-L6-B8
A1-L6-B9
A1-L6-B10
A1-L6-B11
A1-L6-B12
A1-L6-B13
A1-L7-B1
A1-L7-B2
A1-L7-B3
A1-L7-B4
A1-L7-B5
A1-L7-B6
A1-L7-B7
A1-L7-B8
A1-L7-B9
A1-L7-B10
A1-L7-B11
A1-L7-B12
A1-L7-B13
A1-L8-B1
A1-L8-B2
A1-L8-B3
A1-L8-B4
A1-L8-B5
A1-L8-B6
A1-L8-B7
A1-L8-B8
A1-L8-B9
A1-L8-B10
A1-L8-B11
A1-L8-B12
A1-L8-B13
A1-L9-B1
A1-L9-B2
A1-L9-B3
A1-L9-B7
A1-L9-B8
A1-L9-B9
A1-L9-B11
A1-L9-B13
A1-L20-B1
A1-L20-B2
A1-L20-B3
A1-L20-B4
A1-L20-B5
A1-L20-B6
A1-L20-B7
A1-L20-B8
A1-L20-B9
A1-L20-B10
A1-L20-B11
A1-L20-B12
A1-L20-B13
A1-L21-B1
A1-L21-B2
A1-L21-B3
A1-L21-B4
A1-L21-B5
A1-L21-B6
A1-L21-B7
A1-L21-B8
A1-L21-B9
A1-L21-B10
A1-L21-B11
A1-L21-B12
A1-L21-B13
A1-L22-B1
A1-L22-B2
A1-L22-B3
A1-L22-B4
A1-L22-B5
A1-L22-B6
A1-L22-B7
A1-L22-B8
A1-L22-B9
A1-L22-B10
A1-L22-B11
A1-L22-B12
A1-L22-B13
A1-L23-B1
A1-L23-B2
A1-L23-B3
A1-L23-B4
A1-L23-B5
A1-L23-B6
A1-L23-B7
A1-L23-B8
A1-L23-B9
A1-L23-B10
A1-L23-B11
A1-L23-B12
A1-L23-B13
A1-L24-B1
A1-L24-B2
A1-L24-B3
A1-L24-B4
A1-L24-B5
A1-L24-B6
A1-L24-B7
A1-L24-B8
A1-L24-B9
A1-L24-B10
A1-L24-B11
A1-L24-B12
A1-L24-B13
A1-L30-B1
A1-L30-B2
A1-L30-B3
A1-L30-B4
A1-L30-B5
A1-L30-B6
A1-L30-B7
A1-L30-B8
A1-L30-B9
A1-L30-B10
A1-L30-B11
A1-L30-B12
A1-L30-B13
A1-L31-B1
A1-L31-B2
A1-L31-B3
A1-L31-B4
A1-L31-B5
A1-L31-B6
A1-L31-B7
A1-L31-B8
A1-L31-B9
A1-L31-B10
A1-L31-B11
A1-L31-B12
A1-L31-B13
A1-L32-B1
A1-L32-B2
A1-L32-B3
A1-L32-B7
A1-L32-B8
A1-L32-B9
A1-L32-B11
A1-L32-B13
A1-L39-B1
A1-L39-B2
A1-L39-B3
A1-L39-B4
A1-L39-B5
A1-L39-B6
A1-L39-B7
A1-L39-B8
A1-L39-B9
A1-L39-B10
A1-L39-B11
A1-L39-B12
A1-L39-B13
A1-L40-B1
A1-L40-B2
A1-L40-B3
A1-L40-B4
A1-L40-B5
A1-L40-B6
A1-L40-B7
A1-L40-B8
A1-L40-B9
A1-L40-B10
A1-L40-B11
A1-L40-B12
A1-L40-B13
A1-L41-B1
A1-L41-B2
A1-L41-B3
A1-L41-B4
A1-L41-B5
A1-L41-B6
A1-L41-B7
A1-L41-B8
A1-L41-B9
A1-L41-B10
A1-L41-B11
A1-L41-B12
A1-L41-B13
A1-L42-B1
A1-L42-B2
A1-L42-B3
A1-L42-B4
A1-L42-B5
A1-L42-B6
A1-L42-B7
A1-L42-B8
A1-L42-B9
A1-L42-B10
A1-L42-B11
A1-L42-B12
A1-L42-B13
A1-L43-B1
A1-L43-B2
A1-L43-B3
A1-L43-B4
A1-L43-B5
A1-L43-B6
A1-L43-B7
A1-L43-B8
A1-L43-B9
A1-L43-B10
A1-L43-B11
A1-L43-B12
A1-L43-B13
A1-L44-B1
A1-L44-B2
A1-L44-B3
A1-L44-B7
A1-L44-B8
A1-L44-B9
A1-L44-B11
A1-L44-B13
A1-L20-B14
A1-L21-B14
A1-L22-B14
A1-L23-B14
A1-L24-B14
A1-L2-B14
A1-L3-B14
A1-L45-B14
A1-L20-B16
A1-L21-B16
A1-L22-B16
A1-L23-B16
A1-L24-B16
A1-L2-B16
A1-L3-B16
A1-L45-B16
A1-L20-B17
A1-L21-B17
A1-L22-B17
A1-L23-B17
A1-L24-B17
A1-L2-B17
A1-L3-B17
A1-L45-B17
A1-L20-B18
A1-L21-B18
A1-L22-B18
A1-L23-B18
A1-L24-B18
A1-L2-B18
A1-L3-B18
A1-L45-B18
A1-L20-B19
A1-L21-B19
A1-L22-B19
A1-L23-B19
A1-L24-B19
A1-L2-B19
A1-L3-B19
A1-L45-B19
A4-L46-B10
A4-L18-B10
A4-L19-B10
A4-L46-B16
A4-L18-B16
A4-L19-B16
A4-L46-B6
A4-L18-B6
A4-L19-B6 and
A1-L45-B10
or a stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog or pharmaceutically acceptable salt thereof.

338 more elements

Facts

Application

17/096,743Filed 12 Nov 2020 · us provisional application

Priority

13 Nov 2019

Published

US 2021/0214316 A115 Jul 2021

Granted

9 Apr 2024

Term ends

Not estimatedThe source records don’t support an estimate.

Classification5 codes

C07D 237/32
Phthalazines: with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
C07J 43/003
Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopentahydrophenanthrene skeleton: not condensed
C07J 71/0047
Nitrogen only: at position 2
C07D
Heterocyclic compounds